Chiome Bioscience Inc.
4583.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | ¥15,657,940 | ¥6,688,599 | ¥7,829,122 | ¥7,854,175 |
| - Cash | ¥2,063,280 | ¥1,325,554 | ¥1,727,270 | ¥1,790,988 |
| + Debt | ¥281,500 | ¥291,000 | ¥184,000 | ¥183,000 |
| Enterprise Value | ¥13,876,160 | ¥5,654,045 | ¥6,285,852 | ¥6,246,187 |
| Revenue | ¥780,809 | ¥682,464 | ¥630,815 | ¥712,932 |
| % Growth | 14.4% | 8.2% | -11.5% | – |
| Gross Profit | ¥432,852 | ¥398,595 | ¥348,858 | ¥422,458 |
| % Margin | 55.4% | 58.4% | 55.3% | 59.3% |
| EBITDA | -¥1,013,505 | -¥1,211,737 | -¥1,235,060 | -¥1,462,129 |
| % Margin | -129.8% | -177.6% | -195.8% | -205.1% |
| Net Income | -¥1,020,776 | -¥1,220,018 | -¥1,242,871 | -¥1,479,895 |
| % Margin | -130.7% | -178.8% | -197% | -207.6% |
| EPS Diluted | -17.54 | -24.62 | -28.26 | -36.74 |
| % Growth | 28.8% | 12.9% | 23.1% | – |
| Operating Cash Flow | -¥1,000,695 | -¥1,069,192 | -¥1,191,009 | -¥1,131,291 |
| Capital Expenditures | ¥0 | ¥0 | ¥0 | ¥0 |
| Free Cash Flow | -¥1,000,695 | -¥1,069,192 | -¥1,191,009 | -¥1,131,291 |